JP2024544920A5 - - Google Patents

Info

Publication number
JP2024544920A5
JP2024544920A5 JP2024527534A JP2024527534A JP2024544920A5 JP 2024544920 A5 JP2024544920 A5 JP 2024544920A5 JP 2024527534 A JP2024527534 A JP 2024527534A JP 2024527534 A JP2024527534 A JP 2024527534A JP 2024544920 A5 JP2024544920 A5 JP 2024544920A5
Authority
JP
Japan
Application number
JP2024527534A
Other languages
Japanese (ja)
Other versions
JPWO2023086499A5 (https=
JP2024544920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049585 external-priority patent/WO2023086499A1/en
Publication of JP2024544920A publication Critical patent/JP2024544920A/ja
Publication of JPWO2023086499A5 publication Critical patent/JPWO2023086499A5/ja
Publication of JP2024544920A5 publication Critical patent/JP2024544920A5/ja
Pending legal-status Critical Current

Links

JP2024527534A 2021-11-10 2022-11-10 イオン液体組成物 Pending JP2024544920A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163277878P 2021-11-10 2021-11-10
US63/277,878 2021-11-10
US202163295197P 2021-12-30 2021-12-30
US63/295,197 2021-12-30
US202263334410P 2022-04-25 2022-04-25
US63/334,410 2022-04-25
US202263380125P 2022-10-19 2022-10-19
US63/380,125 2022-10-19
PCT/US2022/049585 WO2023086499A1 (en) 2021-11-10 2022-11-10 Ionic liquid compositions

Publications (3)

Publication Number Publication Date
JP2024544920A JP2024544920A (ja) 2024-12-05
JPWO2023086499A5 JPWO2023086499A5 (https=) 2025-11-18
JP2024544920A5 true JP2024544920A5 (https=) 2025-11-18

Family

ID=86336440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527534A Pending JP2024544920A (ja) 2021-11-10 2022-11-10 イオン液体組成物

Country Status (9)

Country Link
US (7) US12233111B2 (https=)
EP (1) EP4429704A4 (https=)
JP (1) JP2024544920A (https=)
KR (1) KR20240126450A (https=)
AU (1) AU2022386166A1 (https=)
CA (1) CA3237751A1 (https=)
IL (1) IL312672A (https=)
MX (1) MX2024005705A (https=)
WO (1) WO2023086499A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
WO2025117852A1 (en) * 2023-11-27 2025-06-05 Mayo Foundation For Medical Education And Research Methods and compositions for occluding blood vessels, ablating tissue, and/or deliverying agents to localized areas within a mammal
WO2025184589A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of glucagon-like peptide-1 receptor agonists and uses thereof
WO2025184608A1 (en) * 2024-02-28 2025-09-04 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of an amylin analog and uses thereof
WO2025264979A1 (en) * 2024-06-21 2025-12-26 I2O Therapeutics, Inc. Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amylin receptor agonists and uses thereof
KR102793070B1 (ko) 2024-12-18 2025-04-09 주식회사 티앨씨 염화나트륨-물-글리세린 기반 이온성 액체 및 그 제조 방법

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5124061A (en) 1991-04-01 1992-06-23 Geary Sr Robert J Systemic plant cryoprotection with choline salts
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU7685894A (en) 1993-09-07 1995-03-27 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2202520C (en) 1994-10-13 2000-09-05 Masanobu Takeuchi Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US7654986B2 (en) 2002-07-03 2010-02-02 Novo Nordisk A/S Needle mounting system and a method for mounting a needle assembly
US20040110755A1 (en) 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
GB0228571D0 (en) 2002-12-06 2003-01-15 Novartis Ag Organic compounds
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US7686786B2 (en) 2004-10-21 2010-03-30 Novo Nordiks A/S Dial-down mechanism for wind-up pen
DK1819382T4 (da) 2004-10-21 2024-11-04 Novo Nordisk As Injektionsanordning med torsionsfjeder og drejeligt display
CN100526289C (zh) 2004-12-06 2009-08-12 河北师范大学 无毒离子液体、制备方法及其应用
ES2633917T3 (es) 2005-01-21 2017-09-26 Novo Nordisk A/S Dispositivo de inyección automático con un mecanismo de liberación superior
PL1877119T3 (pl) 2005-01-25 2019-03-29 Novo Nordisk A/S Urządzenie do wstrzykiwania z mechanizmem zwrotnym informującym o końcu dawki
MX2007010539A (es) 2005-02-28 2007-10-17 Unilever Nv Composicion cosmetica mejorada.
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007017053A1 (en) 2005-07-27 2007-02-15 Novo Nordisk A/S Syringe device with a dose limiting mechanism and an additional safety mechanism
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
ATE499962T1 (de) 2005-07-27 2011-03-15 Novo Nordisk As Dosismechanismus für ein injektionsgerät zur begrenzung einer dosiseinstellung entsprechend der verbleibenden arzneimenge
CA2867194C (en) 2005-10-07 2016-10-04 The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー/エス アミリン誘導体
US9132239B2 (en) 2008-10-24 2015-09-15 Novo Nordisk A/S Dial-down mechanism for wind-up pen
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CA2786953A1 (en) 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
DE102010007562A1 (de) 2010-02-10 2011-08-11 sterna biologicals GmbH & Co KG, 35043 Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20140045754A1 (en) 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
CA2837104A1 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Llc Amylin peptides and derivatives and uses thereof
WO2012168431A2 (en) 2011-06-10 2012-12-13 Novo Nordisk A/S Polypeptides
ES2660118T3 (es) 2011-10-05 2018-03-20 Jeffrey M. Golini Composición de colina
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
JP6559394B2 (ja) 2012-12-05 2019-08-14 ミヨシ油脂株式会社 親水性室温イオン液体とその用途
AU2012397212B2 (en) 2012-12-20 2015-11-12 Colgate-Palmolive Company Oral care composition containing ionic liquids
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー/エス Glp−1化合物の経口投薬
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US10449254B2 (en) 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
AU2015249035A1 (en) 2014-11-14 2016-06-02 Zoran Ivanov Compositions and methods for treatment or prophylaxis of a liver condition
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
KR101764018B1 (ko) 2015-11-04 2017-08-16 포항공과대학교 산학협력단 고성능 리튬-황 전지 유-무기 복합 전해질
KR20170052278A (ko) 2015-11-04 2017-05-12 주식회사 엘지생활건강 바이오필름 제거용 구강 조성물
WO2017164627A2 (ko) 2016-03-21 2017-09-28 주식회사 엘지생활건강 바이오필름 억제 또는 제거용 조성물
KR101978828B1 (ko) 2016-03-21 2019-05-15 주식회사 엘지생활건강 바이오필름 제거용 조성물
JP7179354B2 (ja) 2016-08-29 2022-11-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚処置のためのイオン種に基づく局所処方物
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US10293080B2 (en) 2016-10-05 2019-05-21 The Arizona Board Of Regents On Behalf Of Northern Arizona University Ionic liquids that sterilize and prevent biofilm formation in skin wound healing devices
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN106420610B (zh) 2016-10-21 2019-06-11 昆明理工大学 一种离子液体微乳及其应用
US11654112B2 (en) 2016-11-22 2023-05-23 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
US11213497B2 (en) 2017-06-01 2022-01-04 Arizona Board Of Regents On Behalf Of Northern Arizona University Antibiofilm formulations
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN111918644A (zh) 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 用于内部递送的离子液体
AR113996A1 (es) 2017-12-22 2020-07-08 Intervet Int Bv Vacunas líquidas de virus envueltos vivos
EP3768240A4 (en) 2018-03-19 2021-12-22 Cage Bio Inc. COMPOSITIONS OF IONIC LIQUID FOR THE TREATMENT OF ROSACEA
RS63523B1 (sr) 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3781192A1 (en) 2018-04-16 2021-02-24 Merck Patent GmbH Additives for protein formulations to improve thermal stability
US11464738B2 (en) 2018-05-11 2022-10-11 Wisconsin Alumni Research Foundation Ionic liquid-based nanoemulsion formulation for the efficient delivery of hydrophilic and hydrophobic therapeutic agents
WO2020004368A1 (ja) 2018-06-25 2020-01-02 Jcrファーマ株式会社 蛋白質含有水性液剤
CN109464661B (zh) 2018-12-14 2022-05-10 中国科学院过程工程研究所 一种疫苗抗原组合物及其制备方法
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
US20220257767A1 (en) 2019-04-03 2022-08-18 President And Fellows Of Harvard College Ionic liquids for drug delivery
CN115348858A (zh) 2019-11-08 2022-11-15 凯奇生物公司 使用离子液体的托法替尼表面递送
WO2021102084A1 (en) 2019-11-22 2021-05-27 President And Fellows Of Harvard College Ionic liquids for drug delivery
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN115884959A (zh) 2020-04-22 2023-03-31 耶路撒冷希伯来大学伊森姆研究发展有限公司 生物活性的苯酚盐离子络合物
CN115996751A (zh) 2020-04-28 2023-04-21 哈佛大学校长及研究员协会 与离子液体佐剂有关的方法和组合物
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
CN111588846A (zh) 2020-05-21 2020-08-28 中国科学院过程工程研究所 一种疫苗组合物及其制备方法和应用
AU2021325965A1 (en) 2020-08-14 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation
AU2021336289A1 (en) 2020-09-01 2023-05-04 I2O Therapeutics, Inc. Ionic liquid formulations for treating diabetes
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
JP2024518169A (ja) 2021-05-05 2024-04-25 アイ2オー セラピューティクス,インク. 炎症性疾患および自己免疫疾患を処置するためのイオン性液体製剤
WO2022256291A1 (en) 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
WO2022254209A1 (en) 2021-06-04 2022-12-08 Imperial College Innovations Limited Stable composition
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
CN118382429A (zh) 2021-10-08 2024-07-23 哈佛大学校长及研究员协会 用于药物递送的离子液体
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
WO2023110833A1 (en) 2021-12-13 2023-06-22 Novo Nordisk A/S Pharmaceutical formulations comprising a cyclodextrin
EP4486366A1 (en) 2022-03-03 2025-01-08 Cyprumed GmbH Improved oral pharmaceutical formulations of therapeutic peptides and proteins
WO2023187067A1 (en) 2022-03-30 2023-10-05 Novo Nordisk A/S Formulation method
JP2025517031A (ja) 2022-05-27 2025-05-30 ハンチョウ サイウィンド バイオサイエンスィズ カンパニー リミテッド ヒトアミリン類似体、その誘導体およびその使用
US20260108600A1 (en) 2022-10-07 2026-04-23 President And Fellows Of Harvard College Methods and compositions relating to improved ionic liquid adjuvants

Similar Documents

Publication Publication Date Title
JP2024544920A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023001877A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307046451S (https=)
CN307044751S (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
CN307049978S (https=)
CN307049518S (https=)
CN307049107S (https=)
CN307048653S (https=)
BY13167U (https=)
CN307046613S (https=)
BY13166U (https=)